Rural to urban migration contributes to the high burden of asthma in the urban area

Introduction It is unknown whether rural‐urban migration contributes to worse the burden of asthma in the cities. Objectives The aim of this study was to evaluate whether subjects with asthma that migrated from rural areas to a large urban center in Brazil have more severe disease than asthmatic sub...

Full description

Saved in:
Bibliographic Details
Published inThe clinical respiratory journal Vol. 13; no. 9; pp. 560 - 566
Main Authors Ponte, Eduardo Vieira, Lima, Aline, Almeida, Paula Cristina Andrade, de Jesus, Juliana Pires Viana, Souza‐Machado, Adelmir, Barreto, Maurício Lima, Cruz, Álvaro A.
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.09.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Introduction It is unknown whether rural‐urban migration contributes to worse the burden of asthma in the cities. Objectives The aim of this study was to evaluate whether subjects with asthma that migrated from rural areas to a large urban center in Brazil have more severe disease than asthmatic subjects that was born and always lived in the urban area. Methods This is a case‐control study. We enrolled two groups of subjects with asthma currently living in a large urban center in Brazil: 486 subjects with moderate‐severe asthma and 432 subjects with mild asthma. Results Rural‐urban migrants had higher odds of moderate‐severe asthma [adjusted OR 1.57, 95% CI (1.18‐2.01)] and uncontrolled symptoms of asthma [adjusted OR 1.80, 95% CI (1.16‐2.76)] than urban‐born subjects. Conclusions Rural‐urban migrants in Brazil have more severe asthma than urban‐born subjects. Our results suggest that rural‐urban migration is associated with the high burden of asthma in the urban area.
Bibliography:Funding information
This study was funded by CNPq‐Brazil, FAPESB‐Brazil (PRONEX 020/2009, grant# 6353 PNX 0018/2009) and GlaxoSmilthKline (Program Trust in Science). Àlvaro A Cruz reports grants from National Research Council of Brazil and GSK, and personal fees from AstraZeneca, Novartis, Boehringer Ingelheim, Merck, Sharp & Dohme, GSK, Sanofi and CHIESI.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:1752-6981
1752-699X
1752-699X
DOI:10.1111/crj.13058